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wheezy infants/preschoolersTo the Editor
We read with interest the article by Brand et al.1 regarding
the use of ciclesonide in wheezy preschool children. Dis-
cussing their results, the authors mention our systematic
review on the efficacy of ICS in infants/preschoolers with
wheeze or asthma, published a couple of years ago.2 Brand
and colleagues stated on it: “Although a recent meta-
analysis of preschool wheezing studies showed superiority
of ICS over placebo, there was a high degree of clinical and
statistical heterogeneity between studies..”
However, we totally disagree with this assertion;
because, our systematic review showed that effects sizes
were consistent, with only two outcomes explored (mean
change from baseline in symptom score and in albuterol
use) showing substantial statistical heterogeneity. On the
contrary, primary outcome (wheezing/asthma exacerba-
tions [WAEs]), and the remainder secondary outcomes
(withdrawals caused by WAEs and mean change from
baseline in PEF and FEV1) were statistically homogeneous
(I2 Z 10% and I2 Z 0%, respectively). Concerning clinical
heterogeneity, we performed a sensitivity analysis of the
primary outcome to explore the influence of different
factors such as the type of disease, age, atopic status,
methodological quality of studies, method of ICS delivery,
and ICS choice. Although a clinical and statistical WAE
reduction appeared in both wheeze and asthmatic groups,
subgroup analysis suggests that this effect could be more
relevant in children with a diagnosis of asthma. On the
other hand, this beneficial effect was independent of age,
atopic condition, type of ICS (budesonide or fluticasone),
mode of delivery, and study quality and duration.
Curiously, regarding the results of the Brand and
colleagues, they appear as consistent with our review.
Thus, we found that treatment of 7 subjects with ICS
therapy prevents one child from experiencing a WAE (95%DOI of original articles: http://dx.doi.org/10.1016/j.rmed.2011.
12.023, http://dx.doi.org/10.1016/j.rmed.2011.07.017.
0954-6111/$ - see front matter ª 2012 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2012.10.010CI, 6e9), while in the study of Brand and colleagues de
number needed to treat was 16. However, the WAE rate in
this study was largely lower than estimated based on
most of the previous clinical trials in this age group, and
in the author’s own words “an unexpectedly large
placebo response was observed which may have obscured
beneficial effects of ciclesonide therapy on symptom
scores” and this finding “suggest however that the
patients recruited had milder disease than expected”. It
should be noted that both studies used an identical WAE
definition. Finally, the benefits in pulmonary function
due to the use of ICS were virtually the same in both
studies.
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